apomab

10/01/2009 - "In vivo, Apomab exerted remarkable tumor suppressive activity leading to complete regression of well-advanced mammary tumors. "
01/01/2009 - "Here, we aim to image tumor uptake of APOMAB (DAB4) and to define its biological correlates. "
08/01/2008 - "Apomab demonstrates preclinical activity against a range of solid tumors, both as monotherapy and in combination with cytotoxics. "
04/01/2008 - "In vitro, Apomab triggered apoptosis in cancer cells, while sparing normal hepatocytes even upon anti-Fc crosslinking. "
12/01/2008 - "Similarly, histologic analysis revealed that apomab, chemotherapy, or the combination significantly reduced tumor size compared with vehicle, whereas the combination induced significantly greater reduction in tumor size than did chemotherapy or apomab. "

12/01/2008 - "To test apomab activity in a setting that may more closely mimic lung cancer pathology in patients, we developed a lung orthotopic model. "
12/01/2008 - "Several lung cancer cell lines express DR5 and exhibit apoptosis in response to apomab in vitro. "
12/01/2008 - "These results show a positive interaction of apomab with chemotherapy, evidenced by significant inhibition of tumor growth as well as improved survival, thus supporting further investigation of this therapeutic approach in lung cancer patients."

12/01/2008 - "We investigated the efficacy of apomab and its interaction with chemotherapy in xenograft models based on human NCI-H460 non-small-cell lung carcinoma cells. "

10/01/2009 - "In this study, we assessed the cytotoxic effect of Apomab in vitro and evaluated its antitumor activity in murine models of breast cancer development and progression. "
10/01/2009 - "Apomab represents a potent immunotherapeutic agent with strong activity against the development and progression of breast cancer and should be evaluated in patients with primary and metastatic disease."
10/01/2009 - "In vitro, Apomab treatment induced apoptosis in a panel of breast cancer cell lines but was without effect on normal human primary osteoblasts, fibroblasts, or mammary epithelial cells. "
10/01/2009 - "Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer."
10/01/2009 - "In contrast, treatment with Apomab following an early treatment protocol inhibited both intraosseous and extraosseous tumor growth and prevented breast cancer-induced osteolysis. "

04/01/2008 - "In vivo, Apomab exerted potent antitumor activity as a single agent or in combination with chemotherapy in xenograft models, including those based on colorectal, non-small cell lung and pancreatic cancer cell lines. "